Aspirin-triggered resolvin D1 (AT-RvD1, 15R-RvD1) is a specialized pro-resolving mediator biosynthesized when aspirin-acetylated COX-2 converts DHA to 17R-hydroxy-DHA, which is then processed by 5-LOX to produce the 15R-epimer of resolvin D1. Despite differing only in stereochemistry (15R vs 15S configuration) from endogenous RvD1, AT-RvD1 exhibits equal or superior potency at terminating neutrophil recruitment, enhancing Efferocytosis, and actively promoting inflammatory resolution through dual receptor signaling.
Think of inflammation as a house fire. Most anti-inflammatory drugs are like turning off the gas supply—they stop new fuel from feeding the flames (COX-2 inhibition), but they don't actively put out the fire or clean up the damage. AT-RvD1 is the fire brigade that arrives after aspirin has modified the building's alarm system (COX-2 acetylation). Instead of producing alarm signals (prostaglandins), the acetylated alarm now produces "all-clear" signals (17R-HDHA precursor). The local contractor (5-LOX) then converts this into specialized cleanup crews (AT-RvD1) that stop more firefighters from arriving (halting neutrophil infiltration), actively remove debris (enhancing macrophages clearance of dead cells), and even repair the smoke detectors (reducing pain sensitivity at TRPV1 channels). The "R" configuration is like having the cleanup crew arrive from a different entrance (aspirin pathway) versus the usual door (endogenous synthesis), but they do the same job—sometimes even more efficiently because they're less likely to be degraded by tissue enzymes.
AT-RvD1 biosynthesis requires a two-enzyme sequential pathway initiated by aspirin:
- Aspirin acetylation → Acetyl-COX-2 (covalent modification at Ser530)
- Acetyl-COX-2 + DHA → 17R-hydroxy-DHA (instead of pro-inflammatory prostaglandins)
- 17R-HDHA + 5-LOX → AT-RvD1 (7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid)
Receptor signaling cascade:
AT-RvD1 → ALX/FPR2 binding (Gi-protein coupled):
- Inhibits NF-κB nuclear translocation → ↓ TNF-α, IL-1β, IL-6 transcription
- Activates RhoA/ROCK pathway → cytoskeletal rearrangement stopping neutrophil migration
- ↓ L-selectin/CD62L shedding → prevents neutrophil rolling and extravasation
- ↑ Annexin A1 expression → amplifies resolution signaling
AT-RvD1 → GPR32/DRV1 binding (human-specific receptor):
- Activates PKA pathway → ↑ cAMP → inhibits neutrophil chemotaxis
- ↑ SOCS1/SOCS3 expression → cytokine receptor desensitization
- ↑ PPARγ activation → M2 macrophages polarization
- ↑ CD206, CD163 expression → enhanced phagocytic capacity
Efferocytosis enhancement:
- AT-RvD1 → ↑ phosphatidylserine recognition on apoptotic cells
- ↑ MerTK, integrin αvβ3 expression on macrophages → binding apoptotic cells
- ↑ RhoA inactivation → cytoskeletal reorganization for engulfment
- ↑ PPAR-γ → ↑ CD36, C1q → improved apoptotic cell clearance (up to 3-fold increase)
Pain modulation:
- Direct TRPV1 channel antagonism (IC50 ~10-100 nM)
- TRPA1 channel inhibition → reduced nociceptor sensitization
- Spinal dorsal horn: ↓ ERK1/2 phosphorylation → ↓ central sensitization
- ↓ Substance P release from primary afferents
graph TD
A[Aspirin] -->|acetylates Ser530| B[COX-2-Acetyl]
C[DHA] --> B
B --> D[17R-HDHA]
D -->|5-LOX| E[AT-RvD1]
E --> F[ALX/FPR2]
E --> G[GPR32/DRV1]
F --> H["↓ NF-κB"]
F --> I["↓ Neutrophil migration"]
F --> J["↑ Annexin A1"]
G --> K["↑ cAMP/PKA"]
G --> L["↑ SOCS1/3"]
G --> M["↑ PPARγ"]
H --> N["↓ TNFα, IL-1β, IL-6"]
I --> O[Resolution of inflammation]
M --> P[M2 Macrophage polarization]
P --> Q[Enhanced efferocytosis]
Q --> O
E --> R[TRPV1/TRPA1 inhibition]
R --> S["↓ Pain signaling"]
Temporal dynamics:
- Peak AT-RvD1 synthesis: 2-6 hours post aspirin + DHA co-administration
- Plasma half-life: 4-8 minutes (rapid local action, then enzymatic inactivation)
- Tissue half-life: 15-45 minutes depending on local enzyme activity
- Optimal dosing: Aspirin 75-100 mg + DHA 1-2g daily maintains production
AT-RvD1 represents a fundamental shift from "anti-inflammation" to "pro-resolution"—the difference between stopping damage and actively healing. This is critical in cPNI because many chronic inflammatory conditions (rheumatoid arthritis, IBD, chronic pain, Alzheimer's Disease) reflect a failure of resolution rather than excessive initiation.
Metamodel connections:
- Metamodel 1 (Evolutionary Mismatch): Modern Omega-3 deficiency impairs AT-RvD1 substrate availability; ancestral intake (~2-3g EPA+DHA/day) supported robust resolution capacity
- Selfish Immune System: When DHA is scarce, the immune system hoards it for cell membranes rather than SPM production, prioritizing survival over resolution
- Metamodel 3 (Thrifty Metabolism): chronic inflammation depletes DHA stores rapidly; AT-RvD1 production requires ongoing replenishment
Clinical applications:
Chronic inflammatory conditions:
- Target serum Omega-3 index >8% for optimal SPM production
- Combine low-dose aspirin (75-100 mg) with high-quality fish oil (EPA+DHA >2g)
- Monitor CRP (<1 mg/L), IL-6 (<2 pg/mL), and erythrocyte sedimentation rate as resolution biomarkers
- AT-RvD1 deficiency suspected when inflammation persists despite removal of triggers
Pain management:
- Neuropathic pain: AT-RvD1 reduces TRPV1 sensitization at picomolar concentrations
- Postoperative: Pre-surgical Omega-3 loading (2 weeks, 3-4g/day) enhances AT-RvD1 production capacity
- Fibromyalgia/chronic widespread pain: Often shows low resolution index (RvD1:LTB4 ratio <0.1)
Neurodegenerative disease:
Autoimmune conditions:
Intervention strategy (cPNI 5+2 protocol integration):
- Substrate provision: DHA 1-2g/day (measured via Omega-3 index)
- Enzyme optimization: Low-dose aspirin 75-100 mg (acetylates COX-2)
- Cofactors: Vitamin E (prevents DHA oxidation), B vitamins (support resolution enzyme function)
- Remove inhibitors: High Omega-6:Omega-3 ratios (>10:1) compete for 5-LOX
- Lifestyle: Exercise and cold exposure upregulate COX-2 expression (more substrate for acetylation)
Biomarker monitoring:
- Direct: Plasma AT-RvD1 (specialized lipid profiling, reference >50 pg/mL)
- Indirect: Resolution index (RvD1+AT-RvD1:LTB4 ratio >1.0 indicates active resolution)
- Clinical: Time to pain reduction, swelling resolution, functional restoration
- AT-RvD1 is 10-100x more potent at promoting resolution than at inhibiting neutrophil infiltration (stereoselective receptor binding)
- Requires both aspirin (to acetylate COX-2 at Ser530) and adequate DHA substrate (>1g/day oral intake)
- Half-life of 4-8 minutes in plasma, 15-45 minutes in tissues, requiring ongoing synthesis for sustained effects
- Reduces pain at picomolar to nanomolar concentrations (10-100 nM IC50 at TRPV1) in preclinical models
- Enhances bacterial clearance 2-3 fold while reducing excessive inflammation (maintains antimicrobial function)
- Production peaks 2-6 hours after aspirin + DHA co-administration; timing matters for perioperative applications
- 15R stereochemistry (aspirin pathway) is equipotent to 15S (RvD1, endogenous pathway) but more resistant to eicosanoid oxidoreductase degradation
- Binds two GPCRs: ALX/FPR2 (expressed broadly) and GPR32/DRV1 (human-specific, not in rodents—limits animal model translation)
- Increases macrophage Efferocytosis capacity up to 3-fold at nanomolar concentrations
- Aspirin 75-100 mg acetylates ~95% of platelet COX-2 within 2 hours; higher doses offer no additional AT-RvD1 benefit
- Omega-3 index <4% associated with 70% reduction in SPM synthesis capacity versus >8% index
- Clinical AT-RvD1 deficiency manifests as "sterile inflammation"—tissue damage without infection, poor wound healing
- Specialized pro-resolving mediators — AT-RvD1 is a key member of the SPM family, representing aspirin-modified resolution pathway
- Aspirin-triggered resolvins — AT-RvD1 is the primary D-series aspirin-triggered resolvin; also includes AT-PD1 from same pathway
- DHA — Absolute substrate requirement; AT-RvD1 synthesis directly proportional to DHA bioavailability
- aspirin — Covalent acetylation of COX-2 is obligate first step; explains aspirin's benefits beyond prostaglandin inhibition
- COX-2 acetylation — Aspirin's acetyl group on Ser530 switches COX-2 from pro-inflammatory to pro-resolving enzyme
- 5-LOX — Second enzymatic step converting 17R-HDHA to AT-RvD1; polymorphisms affect production capacity
- ALX/FPR2 — Primary AT-RvD1 receptor mediating anti-inflammatory and pro-efferocytotic effects
- GPR32 — Human-specific AT-RvD1 receptor (DRV1); explains species differences in resolution capacity
- Efferocytosis — AT-RvD1 enhances macrophage clearance of apoptotic cells 2-3 fold, critical for tissue repair
- neutrophils — AT-RvD1 stops neutrophil infiltration (chemotaxis, transmigration) while preserving antimicrobial oxidative burst
- macrophages — Promotes M2 polarization, enhances phagocytic capacity, and stimulates anti-inflammatory cytokine production
- inflammatory resolution — Primary function is actively driving resolution phase, not merely suppressing inflammation
- NF-κB — AT-RvD1 prevents NF-κB nuclear translocation, limiting pro-inflammatory gene transcription
- TRPV1 — Direct channel antagonism reduces nociceptor sensitization and thermal hyperalgesia
- TRPA1 — Inhibits TRPA1 activation reducing mechanical and chemical pain signaling
- pain — AT-RvD1 reduces both peripheral nociceptor activation and spinal cord central sensitization
- Omega-3 fatty acids — EPA and DHA are substrate pool; Omega-3 index >8% optimal for SPM synthesis
- chronic inflammation — Deficient AT-RvD1 production contributes to failure of inflammatory resolution in chronic diseases
- RvD1 — Endogenous 15S-epimer; AT-RvD1 is 15R-aspirin-triggered form with similar potency but different biosynthesis
- Lipid mediator class switching — Aspirin enables switch from pro-inflammatory prostaglandins to pro-resolving AT-RvD1
- COX-2 — Enzyme substrate; acetylated form produces resolution precursors instead of inflammatory prostaglandins
- Resolvins — AT-RvD1 is D-series resolvin; part of larger resolvin family including E-series, T-series
- neuroprotection — Reduces neuroinflammation in Alzheimer's Disease, Parkinson's, stroke models
- rheumatoid arthritis — Animal models show reduced joint inflammation, cartilage protection, enhanced synovial healing
- colitis — Promotes mucosal barrier repair and reduces intestinal inflammation in IBD models
- Alzheimer's Disease — Reduces microglial activation, enhances amyloid-β clearance, protects synaptic density
- R-epimers — 15R stereochemistry distinguishes AT-RvD1 from endogenous 15S-RvD1; both are bioactive
- atorvastatin — Statins may enhance AT-RvD1 production via COX-2 upregulation (pleiotropic statin effect)
- IL-6 — AT-RvD1 reduces IL-6 transcription via NF-κB inhibition; useful in cytokine storm scenarios
- TNF-α — Suppresses TNF-α production in macrophages and reduces TNF-α receptor sensitivity
- Chronic pain — Addresses central sensitization and peripheral nociceptor activity; useful in neuropathic and inflammatory pain
- Oxidative Stress — AT-RvD1 reduces neutrophil oxidative burst in tissues while maintaining antimicrobial function
- Innate immunity — Modulates innate immune cell function without suppressing pathogen clearance
- M2 macrophages — AT-RvD1 is potent M2 polarization signal via PPARγ activation
- autophagy — Enhances LC3-II/LC3-I ratio in macrophages, promoting clearance of intracellular debris